Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Status:
Completed
Trial end date:
2009-02-24
Target enrollment:
Participant gender:
Summary
Primary
• Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid
supplementation when administered to patients with relapsed or refractory peripheral T-cell
lymphoma (PTCL)
Secondary
- Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid
supplementation when administered to patients with relapsed or refractory PTCL
- Determine the pharmacokinetic (PK) profile of pralatrexate when administered with
vitamin B12 and folic acid supplementation